25 Aug Multiple Sclerosis: Decrease in Relapses and Brain Lesions with Ublituximab, Targeting B Cells
MedicalResearch.com Interview with:
Prof. Steinman
Prof. Lawrence Steinman MD
Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics
Beckman Center for Molecular Medicine Stanford University
Stanford, CA
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: We are publishing the results of two successful phase 3 trials in relapsing MS (multiple sclerosis).
We tested a glycoengineered antibody to B cells. The glycoengineered antibody are more potent in killing the target. They can be delivered more easily.
MedicalResearch.com: What should readers take away from your report?
Response: The reduction in relapses was better than any reported by other anti-CD20 antibodies. A barrier of 0.1 relapses per year had never been broken. Here in both trials the results showed fewer than 0.1 relapse per year, or in other words. less than one relpase in 10 years.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Since multiple sclerosis is triggered by an infection in B cells, combining antibodies that kill the infected cells with an anti-viral might be worthwhile to test.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: We also saw a statistically significant increase in disability improvement in these trials.
Citation:
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis Lawrence Steinman, M.D., Edward Fox, M.D., Ph.D., Hans-Peter Hartung, M.D., Enrique Alvarez, M.D., Ph.D., Peiqing Qian, M.D., Sibyl Wray, M.D., Derrick Robertson, M.D., DeRen Huang, M.D., Ph.D., Krzysztof Selmaj, M.D., Ph.D., Daniel Wynn, M.D., Gary Cutter, Ph.D., Koby Mok, Ph.D., Yanzhi Hsu, Ph.D., Yihuan Xu, Ph.D., Michael S. Weiss, J.D., Jenna A. Bosco, B.S., Sean A. Power, B.S., Lily Lee, Ph.D., Hari P. Miskin, M.Sc., and Bruce A.C. Cree, M.D., Ph.D., for the ULTIMATE I and ULTIMATE II Investigators*
N Engl J Med 2022;387:704-14. DOI: 10.1056/NEJMoa2201904
https://www.nejm.org/doi/full/10.1056/NEJMoa2201904
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on August 25, 2022 by Marie Benz MD FAAD